US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Over 537 million people globally suffer from diabetes, with 227 million in Asia Pacific. More than half may develop diabetic ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

Diabetic macular edema can result in low vision or ... When fluid gets into the retina’s center part, called the macula, it causes swelling. This can affect vision and, in some cases, lead ...

A hospital has launched a specialist "state-of-the-art" £250,000 ophthalmology suite for eye procedures. Kettering General ...

VEGF is a mediator in the pathogenesis of certain eye conditions, including wet age-related macular degeneration (AMD), diabetic retinopathy and macular oedema secondary to retinal vein occlusions.

The following is a summary of “How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient ...

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).